Hepatocellular Carcinoma Excellence Forum

Hepatocellular Carcinoma

Excellence Forum

Leaders in the field sharing authoritative insights and institutional best practices.

Laura Dawson, MD, Princess Margaret Cancer Care

Videos

Addition of SBRT to Sorafenib for Patients With Locally Advanced Hepatocellular Carcinoma

03/11/2025

Laura Dawson, MD, discusses the results of a phase 3 study comparing stereotactic body radiotherapy followed by sorafenib to sorafenib alone for patients with locally advanced hepatocellular carcinoma.

Laura Dawson, MD, discusses the...

03/11/2025

Oncology

Videos

Tiragolumab Plus Atezolizumab and Bevacizumab for Patients With Hepatocellular Carcinoma

03/05/2025

Richard Finn, MD, discusses results from the phase 1b/2 MORPHEUS-Liver trial which demonstrated that the addition of tiragolumab to atezolizumab plus bevacizumab showed promise for patients with previously untreated, locally advanced or...

Richard Finn, MD, discusses...

03/05/2025

Oncology

Novel Electromagnetic Field Device for Advanced Hepatocellular Carcinoma

02/27/2025

According to study results, a novel device, which emits electromagnetic fields that are amplitude-modulated at hepatocellular carcinoma frequencies, was found to have a reasonable assurance of safety and probable benefit.

According to study results, a...

02/27/2025

Oncology

Christopher Manz, MD, MSPH, Dana-Farber Cancer Institute

Videos

Treatment Patterns for Hepatocellular Carcinoma

12/18/2024

Christopher Manz, MD, MSHP, discusses results from a retrospective study evaluating the evolving treatment patterns for hepatocellular carcinoma.

Christopher Manz, MD, MSHP,...

12/18/2024

Oncology

Riccardo Lencioni, MD, University of Pisa School of Medicine

Videos

Addition of Durvalumab, Bevacizumab to TACE for Hepatocellular Carcinoma Improves PFS

01/23/2024

Riccardo Lencioni , MD;

Ricardo Lencioni, MD, shares results from the phase 3 EMERALD-1 study which found the addition of durvalumab and bevacizumab to TACE improved progression-free survival among patients with hepatocellular carcinoma, compared with TACE alone.

Ricardo Lencioni, MD, shares...

01/23/2024

Oncology

Quiz

STRIDE vs Sorafenib for Unresectable Hepatocellular Carcinoma

10/05/2023

Which treatment was associated with a better chance of survival at 4 years for patients with unresectable hepatocellular carcinoma?

Which treatment was associated...

10/05/2023

Oncology

Bruno Sangro, MD, PhD, Clínica Universidad de Navarra

Videos

Long-Term OS Benefit of STRIDE Regimen Among Patients With Unresectable Hepatocellular Carcinoma

08/21/2023

Bruno Sangro , MD, PhD;

At the 2023 World Congress on Gastrointestinal Cancers, Bruno Sangro, MD, PhD, discusses 4-year overall survival results from the phase 3 HIMALYA study.

At the 2023 World Congress on...

08/21/2023

Oncology

Laura Dawson, MD, Princess Margaret Cancer Center

Videos

Stereotactic Body Radiotherapy Plus Sorafenib Improved Survival Outcomes for Patients With Hepatocellular Carcinoma Compared to Sorafenib Alone

01/20/2023

At the 2023 ASCO Gastrointestinal Symposium, Laura Dawson, MD, shares updated data from the NRG/RTOG 1112 trial evaluating stereotactic body radiotherapy plus sorafenib compared with sorafenib for hepatocellular carcinoma.

At the 2023 ASCO...

01/20/2023

Oncology

Videos

Palliative Radiotherapy Improves Pain for Patients With Symptomatic Hepatocellular Carcinoma and Liver Metastases

01/20/2023

At the 2023 ASCO Gastrointestinal Symposium, Laura Dawson, MD, shares results from a study evaluating palliative radiotherapy for hepatocellular carcinoma and liver metastases.

At the 2023 ASCO...

01/20/2023

Oncology

Andrea Casadei-Gardini, MD, San Raffaele Hospital

Videos

Lenvatinib Demonstrates Significant Benefit vs Atezolizumab Plus Bevacizumab for Hepatocellular Carcinoma

07/02/2022

Andrea Casadei-Gardini, MD, discusses findings from an international study examining atezolizumab plus bevacizumab vs lenvatinib or sorafenib in patients with non-viral unresectable hepatocellular carcinoma.

Andrea Casadei-Gardini, MD,...

07/02/2022

Oncology

Recent News

FDA Approval

FDA Approves Pembrolizumab for Patients With HER2-Positive, PD-L1 Expressing Gastric or Gastroesophageal Junction Adenocarcinoma

03/19/2025

Stephanie Holland ;

Based on results from the KEYNOTE-811 study, the FDA has approved first-line pembrolizumab plus trastuzumab, fluoropyrimidine, and platinum-containing chemotherapy for patients with locally advanced, unresectable, or metastatic HER2-positive...

Based on results from the...

03/19/2025

Oncology

News

HMP Global’s Great Debates in Solid Tumors events deliver best of three popular oncology conferences

03/19/2025

The best of HMP Global’s three Great Debates programs will be featured in one 2025 series, Great Debates in Solid Tumors, delivering a more comprehensive learning experience for oncology clinicians in the gastrointestinal, women’s and lung...

The best of HMP Global’s three...

03/19/2025

Oncology

Conference Coverage

Addition of Pembrolizumab Does Not Significantly Worsen Quality-of-Life Outcomes for Patients With pMMR Advanced or Recurrent Endometrial Cancer

03/18/2025

Stephanie Holland ;

According to results from the phase 3 NRG GY018 trial, the addition of pembrolizumab to chemotherapy did not significantly worsen patient-reported quality of life outcomes among patients with proficient mismatch repair advanced or recurrent...

According to results from the...

03/18/2025

Oncology

Conference Coverage

Puxitatug Samrotecan Demonstrated Promise for Patients With B7-H4–Positive Advanced or Recurrent Endometrial Cancer

03/18/2025

Stephanie Holland ;

According to results from the phase 1/2a BLUESTAR study, puxitatug samrotecan demonstrated promising efficacy and safety among patients with B7-H4–positive advanced or recurrent endometrial cancer.

According to results from the...

03/18/2025

Oncology

News

Brentuximab Vedotin Plus Lenalidomide and Rituximab Improves Survival For Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma

03/17/2025

Emily Estrada ;

For patients with relapsed/refractory diffuse large B-cell lymphoma, brentuximab vedotin plus lenalidomide and rituximab was associated with improved survival rates and tolerability, according to results from a phase 3 study.

For patients with...

03/17/2025

Oncology

News

Denileukin Diftitox-CXDL Demonstrates Efficacy for Relapsed/Refractory Cutaneous T-Cell Lymphoma

03/17/2025

Emily Estrada ;

A recent phase 3 trial evaluating the use of denileukin diftitox-CXDL for relapsed/refractory cutaneous T-cell lymphoma demonstrated reduced skin tumor burden and promising tolerability.

A recent phase 3 trial...

03/17/2025

Oncology

News

Mutation Clearance After Allogeneic Stem Cell Transplantation as Prognostic Indicator for Patients With Myelofibrosis

03/17/2025

Emily Estrada ;

For patients with myelofibrosis undergoing allogeneic hematopoietic stem cell transplantation, mutation driver clearance at 30 days was associated with improved cancer outcomes, according to study results.

For patients with myelofibrosis...

03/17/2025

Oncology

News

Atezolizumab Plus Bevacizumab and Chemotherapy Fails to Improve Survival for EGFR-Mutated Non-Small Cell Lung Cancer

03/14/2025

Stephanie Holland ;

Results from the phase 3 ETOP 15-19 ABC-lung trial demonstrated that atezolizumab plus bevacizumab and chemotherapy failed to improve survival outcomes for patients with EGFR-mutated non-small cell lung cancer that is resistant to TKIs.

Results from the phase 3 ETOP...

03/14/2025

Oncology

News

Neoadjuvant Tyrosine Kinase Inhibitor Therapy to Downstage Patients With Unresectable Differentiated Thyroid Cancers

03/13/2025

Stephanie Holland ;

Results from a retrospective review demonstrated that administration of neoadjuvant tyrosine kinase inhibitor therapy can effectively downstage patients with unresectable differentiated thyroid cancers, allowing patients to achieve R0...

Results from a retrospective...

03/13/2025

Oncology

News

Lenvatinib Plus Pembrolizumab for Patients With Radioiodine-Refractory Differentiated Thyroid Cancer

03/13/2025

Stephanie Holland ;

According to results from a multi-cohort study, lenvatinib plus pembrolizumab demonstrated efficacy and safety among patients with progressive, radioiodine-refractory differentiated thyroid cancer.

According to results from a...

03/13/2025

Oncology